Cargando…
The Pricing of Breakthrough Drugs: Theory and Policy Implications
Pharmaceutical sales exceed $850 billion a year, of which 84% are accounted for by brand drugs. Drug prices are the focus of an ongoing heated debate. While some argue that pharmaceutical companies exploit monopolistic power granted by patent protection to set prices that are “too high”, others clai...
Autores principales: | Levy, Moshe, Rizansky Nir, Adi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244177/ https://www.ncbi.nlm.nih.gov/pubmed/25422889 http://dx.doi.org/10.1371/journal.pone.0113894 |
Ejemplares similares
-
Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices
por: Orenstein, David M., et al.
Publicado: (2015) -
Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
por: Carl, David L, et al.
Publicado: (2021) -
Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in Malaysia
por: Babar, Zaheer Ud Din, et al.
Publicado: (2007) -
Congestion Pricing Policies and Safety Implications: a Scoping Review
por: Singichetti, Bhavna, et al.
Publicado: (2021) -
Environmental policy and equity prices
por: Lehnert, Thorsten
Publicado: (2023)